TherapeuticsMD (TXMD) Net Cash Flow (2010 - 2026)

TherapeuticsMD has reported Net Cash Flow for 17 years, with the latest figure at $944000.0 in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 35.05% year-over-year to $944000.0; the trailing twelve-month figure through Mar 2026 stood at $2.7 million (up 28.65% YoY), and the FY2025 full-year result was $2.5 million, up 109.74% from the prior year.
• Net Cash Flow for Q1 2026 stood at $944000.0, up from $375000.0 in the prior quarter.
• The five-year high for Net Cash Flow was $19.5 million in Q3 2022, with the low at -$140.8 million in Q2 2022.
• Historically, Net Cash Flow has averaged -$14.3 million across 5 years, with a median of -$71000.0 in 2024.
• Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 437.54% — and 2025, when it surged 2105.88%.
• TherapeuticsMD's Net Cash Flow stood at -$81.8 million in 2022, then jumped by 96.38% to -$3.0 million in 2023, then soared by 100.57% to $17000.0 in 2024, then surged by 2105.88% to $375000.0 in 2025, then jumped by 151.73% to $944000.0 in 2026.
• The last three Net Cash Flow figures came in at $944000.0 (Q1 2026), $375000.0 (Q4 2025), and $999000.0 (Q3 2025), per Business Quant data.